

DOORS THAT OPEN TOWARD NEW BEGINNINGS



OPPORTUNITY




The introduction of ODIN's science occurs at a time when the \$600 billion pharmaceutical industry is poised for an extraordinary transformation. An era of surging profits, fueled by blockbuster small-molecule drugs, is grinding to a halt. Research pipelines are running dry, and patent protection is beginning to expire. Pharmaceutical companies are in a period of

discontinuous change where many of the assumptions of the last half century no longer hold true.

At the same time, there exist extensive libraries with countless high-value molecules that have, until now, been cost-prohibitive to produce.

ODIN's science presents an opportunity to the pharmaceutical industry, enabling the

development and manufacture of molecules that have heretofore been impractical to produce in large quantities and therefore have only been produced as limited-quantity specialty or R&D compounds. ODIN's proprietary technology provides production techniques that are readily scalable and highly economical in relation to conventional synthetic routes.



FEATURES AND BENEFITS

ODIN's science helps to:

- Unlock the drug pipeline, enabling the exploration of vast, undeveloped chemical space
- Reestablish strong composition of matter and process patent protection
- Dramatically increase the number of commercially viable, new molecular entities
- Design synthetic schemes with high selectivity and benign environmental effects
- Deliver big margins on molecules that have had small or no profit margins

ODIN's science is a general and enabling method without limitation to the class of compound, reaction type, or set of starting material. It can be quickly adapted to current facilities with very little spatial demand or capital outlay.



ABOUT THE COMPANY

ODIN Industries is a molecular engineering company that has developed a new science that simplifies and accelerates molecular R&D and manufacturing in pharmaceuticals. This is a timely solution that will enable discovery and empower the pharmaceutical industry to optimize profits.

ODIN's proprietary technology, which is available through a competitive licensing offer, makes cutting-edge science and technology commercially viable now, and accelerates research in emerging areas that would not otherwise be viable for many years into the future.

Availability is arguably the primary hurdle to the development of new drug regimens. Even the most potent therapeutic agents are worthless in the clinical setting unless they can be obtained in commercially viable quantities.

Dr. Thomas Johnson
Chairman and CEO
ODIN Industries



LICENSE OPPORTUNITIES

Therapeutics

Blood and Coagulation Disorders
Cardiovascular
CNS Disorders
Dental and Oral
Dermatology
Endocrinology
Gastrointestinal
Gynecologic, Urological
Immunology
Infectious and Viral Diseases
Inflammation and Metabolic Disorders
Musculoskeletal and Connective Tissue Disorders
Nephrology
Oncology
Ophthalmic
Pain
Poison (Antidote)
Respiratory and Pulmonary
Wound Healing and Tissue Repair

Diagnostics

Magnetic Resonance Imaging
Nuclear Medicine
Positron Emission Tomography
X-ray

Drug Delivery

Oral
Intravenous
Pulmonary
Topical

CONTACT US

To learn more about ODIN's science, please contact us for an informational presentation.
We welcome the opportunity to work with you.



ODIN Industries, LLC • 100 Snapfinger Drive • Athens, GA 30605

Tel: (706) 540-7325 • ODINIndustries.com
licensing@ODINIndustries.com